Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 In Vitro Strategies for Evaluating Non-CYP Metabolism Pathways | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

In Vitro Strategies for Evaluating Non-CYP Metabolism Pathways

An overview of these pathways including a discussion of regulatory interest, case examples, in vitro reaction phenotyping approaches and more.

Released By BioIVT

While cytochrome P450 (CYP)-mediated metabolism continues to be of primary concern for the majority of new small molecule drug candidates, efforts to develop compounds that do not have CYP metabolism liability from drug-drug interaction (DDI) and toxicity standpoints have resulted in an increasing number of compounds with significant non CYP-mediated metabolism. However, reaction phenotyping of these enzymes is not always as straightforward as with CYPs because of their diversity and test system limitations. Regardless, regulatory agencies have a safety interest in understanding the metabolism pathways of new drug candidates, and the complexity of elucidating non CYP-mediated metabolism is reflected in their safety requirements.

In April of 2021, Dr. Brian Ogilvie, Vice President of Scientific Consulting at BioIVT, provided an overview of these pathways including a discussion of regulatory interest, case examples, in vitro reaction phenotyping approaches and strategies to evaluate non-CYP enzyme contribution to new drug candidates. This article encompasses the key takeaways from his presentation.


Request more information from BioIVT

Request more information from BioIVT

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters